Look back at pharma news in the week to February 21, 2020

23 February 2020

By Barbara Obstoj-Cardwell. Editor

Last week’s news featured quite a lot relating to the ongoing novel coronavirus (COVID-19) situation, including that Sanofi’s vaccine division joining the band of drugmakers linking with the USA’s BARDA in attempts to develop a vaccine against COVID-19. Elsewhere on the research front, Incyte reported a second positive study for its Jakafi (ruxolitinib) in dermatitis, but Teva Pharmaceutical Industries posted disappointing Phase II/III results for Austedo in Tourette’s syndrome. Regulatory news included Pfizer gaining European approval for its Vyndaqel in the rare condition ATTRR-CM, and BioMarin announced the US Food and Drug Administration had accepted its gene therapy ValRox for priority review.

Sanofi starts work on coronavirus vaccine, bring scale to global research effort

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK